Medicenna Therapeutics Corp. (TSX:MDNA)
0.4400
0.00 (0.00%)
Nov 9, 2026, 2:39 PM EST
Medicenna Therapeutics Employees
Medicenna Therapeutics had 15 employees as of March 31, 2026. The number of employees decreased by 3 or 16.67% compared to the previous year. That makes Medicenna Therapeutics the 39,255th largest employer in the world and 715th in Canada.
Employees
15
Change (1Y)
-3
Growth (1Y)
-16.67%
Revenue / Employee
n/a
Profits / Employee
-1.24M CAD
Market Cap
40.61M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 15 | -3 | -16.67% |
| Mar 31, 2025 | 18 | 2 | 12.50% |
| Mar 31, 2024 | 16 | 0 | - |
| Mar 31, 2023 | 16 | -2 | -11.11% |
| Mar 31, 2022 | 18 | 5 | 38.46% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Medicenna Therapeutics News
- 5 days ago - Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders - GlobeNewsWire
- 14 days ago - Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease - GlobeNewsWire
- 5 weeks ago - Medicenna Announces Results of Annual General and Special Meeting of Shareholders - GlobeNewsWire
- 6 weeks ago - Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting - GlobeNewsWire
- 7 weeks ago - Medicenna Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 7 weeks ago - Medicenna Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences - GlobeNewsWire
- 2 months ago - Medicenna Therapeutics Report: Q1 2027 - Filings